Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Peter M Tessier · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2022 · $218,873 — Emerging SARS-CoV-2 variants are of broad interest because they may be more resistant to current vaccines and associated immune responses. Toward the long-term goal of understanding how receptor-binding domain (RBD) mutations impact transmissibility, it is critical to elucidate the impacts of RBD mu…
Sumant Singh Chugh · RUSH UNIVERSITY MEDICAL CENTER · 2022 · $626,089 — Abstract The COVID 19 pandemic has been associated with the development of proteinuria in up to 40% of hospitalized patients. This cardinal manifestation of kidney disease is most likely related to effects of the extensive cytokine storm in these patients on glomeruli, the filtering units of the kid…
HENRY DANIELL · UNIVERSITY OF PENNSYLVANIA · 2022 · $739,713 — PROJECT SUMMARY/ABSTRACT Current Protein Drugs (PD) are prohibitively expensive ($140 billion in top ten PDs, >75% of global GDP). One third of global population earning <$2 per day can’t afford any PD. Insulin, a five-decade old drug, is still unaffordable, even in developed countries, as illustra…
Noam A Cohen · PHILADELPHIA VA MEDICAL CENTER · 2022 — ABSTRACT Severe acute respiratory syndrome coronavirus SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19) has led to a pandemic with a mortality of approximately 3.5% and a wide range of morbidity outcomes negatively impacted by pre-existing conditions. Given the prevalence of p…
Daniel Kulp · WISTAR INSTITUTE · 2022 · $2,626,814 — Project Summary In December 2019 a novel coronavirus, named sudden acute respiratory syndrome coronavirus-2 (SARS-CoV- 2). SARS-CoV-2 rapidly spread around the globe causing a pandemic disease termed coronavirus disease of 2019 (COVID-19). There have been more than 80 million infections and close to…
ALEXEY VLAD ONUFRIEV · VIRGINIA POLYTECHNIC INST AND ST UNIV · 2022 · $294,013 — Project Summary. This proposal responds to PAR-19-253 “Focused Technology Research and Development”. Our main goal is to develop a novel class of implicit solvation models, as accurate, and even more accurate, than standard explicit solvent models, but much faster. The high accuracy, fast implicit s…
Kelly M. Reavis · PORTLAND VA MEDICAL CENTER · 2022 — Project Background/Rationale: The purpose of this proposal is to quantitatively examine and qualitatively understand the impact of COVID-19 on Veterans' auditory function. Since the pandemic began, over 230,000 Veterans in the VA health care system have tested or been presumed positive for COVID-19.…
JAMES D WEST · VANDERBILT UNIVERSITY MEDICAL CENTER · 2022 · $662,881 — Project Summary: ACE2 shows tremendous promise in the treatment of pulmonary arterial hypertension (PAH). It corrects many of the molecular defects caused by the most common heritable cause of disease, BMPR2 mutation. It has reversed disease in a variety of animal models of PAH, including heritable,…
Michael Edwin Boulton · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2022 · $369,431 — The overarching goal of this project is to determine the role of angiotensin converting enzyme 2 (ACE2) in the diabetic gut, how it impacts hyperglycemia and glycemic variability, and thus contributes to the pathogenesis of diabetic retinopathy (DR). The protective arm of the renin angiotensin syste…
Lee E. EIDEN · NATIONAL INSTITUTE OF MENTAL HEALTH · 2022 · $1,903,701 — The eleven publications from the Section on Molecular Neuroscience (SMN) in the past calendar year comprise eight primary reports arising from data obtained in the laboratory, and three reviews (as well as two additional book chapters in Masterclasses in Neuroendocrinology Volume 12: Neuroanatomy o…
Natalie Shaw · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2022 · $151,959 — We confirmed increased ACE2 mRNA and protein expression and functional activity (via a fluorometric assay) in SMCHD1 KO human placode cells. We are now conducting molecular and genomic studies, including RNA-seq, Hi-C, and SMCHD1 ChIP-seq, studies to investigate the precise mechanism underlying epig…
Giovanna Tosato · DIVISION OF CLINICAL SCIENCES - NCI · 2022 · $847,609 — We have focused on 4 related areas. 1) Our previous studies have identified a critical role of Delta4 (Dll4), an endothelial-specific membrane-bound ligand for Notch1 and Notch4, as a regulator of endothelial cell function. Dll4 is selectively expressed in the developing endothelium a…
Heather Hickman · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $12,746 — The emergence of SARS-CoV-2 in human populations in 2019 has resulted in a global pandemic with staggering morbidity and mortality. In humans, coronavirus-induced disease 2019 (COVID-19) is characterized by decreased lung function and increased pro-inflammatory cytokine production. As the immune m…
Vincent Munster · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $489,519 — The research program of the Virus Ecology Unit (VEU) is focused at understanding the drivers of virus emergence. Upon the emergence of SARS-CoV-2 in 2019, the research we swiftly pivoted to SARS-CoV-2. We were the first was to establish ACE2 as the SARS-CoV-2 receptor and rapidly developed a non-h…
Daniel Barber · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $238,324 — Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has a spectrum of clinical outcomes, ranging from asymptomatic to fatal. There is a need to parse out the role of individual immune cell types and molecular pathways that contribute to effective control of viral infection in asym…
Monica Kraft · UNIVERSITY OF ARIZONA · 2022 · $450,752 — During the first cycle of our AADCRC program, our project focused primarily on Surfactant Protein A (SP-A), a known innate immune modulator that exhibits important anti-inflammatory effects in asthma. In this renewal, we show preliminary data that SP-A binds the interleukin (IL)-6 receptor and disru…
BHAGAVATULA MOORTHY · BAYLOR COLLEGE OF MEDICINE · 2022 · $200,595 — Project Summary Severe coronavirus disease (COVID-19) is caused by a novel Beta-coronavirus, now named SARS-CoV-2. COVID-19 is characterized by unresolved systemic hyperinflammation associated with a life-threatening “cytokine storm syndrome”, leading to multi-organ failure dysfunction in some pati…
KATHLEEN E. RODGERS · UNIVERSITY OF ARIZONA · 2022 · $1,515,611 — PROJECT SUMMARY/ABSTRACT Alzheimer’s disease (AD) is a progressive multifactorial disease affecting more than 50 million people worldwide, and is the most common dementia of late-life. To date, no interventions have demonstrated substantial therapeutic efficacy to prevent, delay or treat AD. In rece…
GR Scott Budinger · NORTHWESTERN UNIVERSITY AT CHICAGO · 2022 · $742,194 — PROJECT SUMMARY This application directly stems from our recent publication in Nature in which we analyzed bronchoalveolar lavage (BAL) fluid from 88 patients with critical SARS-CoV-2 pneumonia using a combination of flow cytometry, bulk transcriptomic profiling of flow sorted alveolar macrophages a…
Eric D Lazartigues · LSU HEALTH SCIENCES CENTER · 2022 · $600,541 — With prevalence as high as 55% for individuals aged 55 and older in United States, hypertension is a major risk factor contributing to cardiovascular diseases (CVD) and global mortality, hence remaining an increasingly important medical and public health issue. The role of the renin-angiotensin syst…